| Similar Articles |
|---|
 |
The Motley Fool
April 29, 2008
Brian Lawler |
Medarex Takes Another Hit Its lead cancer-fighting drug suffers a regulatory delay.   |
The Motley Fool
August 21, 2008
Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool
July 10, 2008
Brian Lawler |
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
The Motley Fool
February 1, 2008
Brian Lawler |
AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
November 8, 2004
Charly Travers |
A Fantastic Cancer-Drug Deal Has Medarex hit the jackpot with MDX-010? Aside from the great financial terms, this deal is an important step in Medarex's transition from a research company to a company with commercial operations. |
The Motley Fool
April 2, 2007
Billy Fisher |
Medarex Not Monkeying Around The stock is a bit speculative at this point, but the anthrax study results are very positive for shareholders. Long-term investors could be rewarded in a big way, should any of Medarex's drugs ultimately become commercialized. |
The Motley Fool
July 24, 2009
Brian Orelli |
Bristol-Myers: Eat or Be Eaten Bristol-Myers Squibb, the oft-rumored acquisition target of partner sanofi-aventis, is doing a little acquiring of its own, which might settle down the rumor mill. |
The Motley Fool
August 29, 2008
Brian Lawler |
Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity? |
Chemistry World
December 6, 2012
Andrew Turley |
Return on drug R&D dropping The pharma industry is getting less and less return on investment in R&D, according to a report. But the trend seems to be bottoming out and -- on a more positive note -- there are more compounds going into late stage development. |
The Motley Fool
April 24, 2007
Brian Lawler |
MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal. |
The Motley Fool
January 28, 2011
Brian Orelli |
Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff. |
The Motley Fool
December 8, 2006
Brian Lawler |
Medarex Takes the Fast Route Medarex's lead drug gets an important yet expected designation from the FDA. Making a pharmaceutical company investment-worthy requires success in the clinic and the laboratory, but it also mandates that companies handle their finances correctly. |
The Motley Fool
March 5, 2010
Brian Orelli |
How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot. |
The Motley Fool
April 26, 2007
Brian Lawler |
AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note. |
BusinessWeek
April 23, 2007
Gene G. Marcial |
Avalon's New Lab Partner: Merck Avalon pharmaceuticals, a little-known biopharma focusing on small-molecule therapeutics for cancer, has teamed up with Big Pharma, including Merck, for the use of its AvalonRx drug discovery system. |
The Motley Fool
October 14, 2010
Sean Williams |
Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away. |
BusinessWeek
December 29, 2010
Kelley & Cortez |
AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs. |
The Motley Fool
June 23, 2009
Brian Orelli |
Wonder Drug! Maybe? Get the facts before jumping on this one. |
The Motley Fool
December 28, 2005
Stephen D. Simpson |
AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either. |
The Motley Fool
October 30, 2009
Brian Orelli |
Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
AstraZeneca Prepares for a Dry Spell A weak late-stage pipeline will make for challenging earnings growth in the coming years. Investors may want to hold out for a better price here. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
The Motley Fool
February 5, 2007
Billy Fisher |
A Fresh Outlook at AstraZeneca Strong performance makes management happy at the European drug giant. As long as the company is able to continue the strong revenue growth from its major contributors, shareholders will be able to enjoy a prosperous 2007. |
BusinessWeek
January 29, 2007
Arlene Weintraub |
More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl. |
The Motley Fool
October 27, 2009
Brian Orelli |
Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions? |
The Motley Fool
April 29, 2011
Brian Orelli |
Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves. |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
Chemistry World
August 2009
Derek Lowe |
Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder |
The Motley Fool
July 30, 2007
Brian Lawler |
AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy. |
The Motley Fool
November 18, 2004
Charly Travers |
A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses. |
The Motley Fool
October 30, 2008
Brian Orelli |
What's on Deck for AstraZeneca? The drugmaker increases EPS by cutting costs, but it's the next move that will count the most. |
The Motley Fool
October 23, 2009
Brian Orelli |
I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared. |
The Motley Fool
February 2, 2006
Stephen D. Simpson |
AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here. |
Chemistry World
April 24, 2007
Victoria Gill |
AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune. |
The Motley Fool
December 11, 2007
Brian Lawler |
Oncology Duo Takes a Gamble With trials complete, Medarex and Bristol-Myers-Squibb plan to submit less-than-stellar data on their skin cancer drug to the FDA. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
